AbbVie gives up patent rights to HIV med Kaletra amid COVID-19 tests: report

With international scrutiny focusing on a narrowing set of drugs currently in tests to treat the symptoms of the novel coronavirus, drugmakers are already facing shortages that could threaten global supply. To counter that demand—and quash accusations of profiteering—Abbvie has reportedly taken a drastic step to open its COVID-19 candidate to competition.